Compare Enveric Biosciences Inc (ENVB) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lumen Technologies Inc — how do they compare? Enveric Biosciences Inc trades at $1.44 (market cap $6.80M), while Lumen Technologies Inc trades at $5.28 (market cap $5.73B). The key difference: Lumen Technologies Inc is far larger — about 842.6× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 17,079,799). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Lumen Technologies Inc for 40 Days on average.
| ENVB | LUMN | |
|---|---|---|
Market Cap | $6.80M | $5.73B |
Volume | 64,867 | 17,079,799 |
Sector | Health | Media |
52-Week High | $10.80 | $11.83 |
52-Week Low | $1.27 | $5.53 |
Typical Hold Time | 14 Days | 40 Days |
Enterprise Value | -$1.49M | $17.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
LUMN trades at $5.91, up 0.08% on the day, with a bearish technical signal. The company reported a net loss of $1.74 billion in 2025, though revenue remains substantial at $12.40 billion. Recent news highlights a Nasdaq listing move and new AI-focused networking services, aiming to capitalize on enterprise demand. Cash flow trends show operational strength but negative net cash flow in 2025. The stock's valuation metrics include a low P/S of 0.47 but negative profitability ratios.
The outlook is mixed, with deep value from low P/S and strategic AI initiatives offering growth potential, but high debt, consistent losses, and bearish analyst consensus pose significant risks. Investors face a speculative turnaround play dependent on successful execution of new strategies amid steep legacy declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
